Elsevier

Fertility and Sterility

Volume 91, Issue 2, February 2009, Pages 456-488
Fertility and Sterility

Polycystic ovary syndrome
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

https://doi.org/10.1016/j.fertnstert.2008.06.035Get rights and content
Under an Elsevier user license
open archive

Objective

To review all available data and recommend a definition for polycystic ovary syndrome (PCOS) based on published peer-reviewed data, whether already in use or not, to guide clinical diagnosis and future research.

Design

Literature review and expert consensus.

Setting

Professional society.

Patients

None.

Intervention(s)

None.

Main Outcome Measure(s)

A systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, to identify studies evaluating the epidemiology or phenotypic aspects of PCOS.

Result(s)

The Task Force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and critiqued by the Androgen Excess and PCOS (AE-PCOS) Society AE-PCOS Board of Directors. No section was finalized until all members were satisfied with the contents, and minority opinions noted. Statements were not included that were not supported by peer-reviewed evidence.

Conclusion(s)

Based on the available data, it is the view of the AE-PCOS Society Task Force that PCOS should be defined by the presence of hyperandrogenism (clinical and/or biochemical), ovarian dysfunction (oligo-anovulation and/or polycystic ovaries), and the exclusion of related disorders. However, a minority considered the possibility that there may be forms of PCOS without overt evidence of hyperandrogenism, but recognized that more data are required before validating this supposition. Finally, the Task Force recognized and fully expects that the definition of this syndrome will evolve over time to incorporate new research findings.

Key Words

Polycystic ovary syndrome
hirsutism
menstrual dysfunction
phenotype
criteria

Cited by (0)

R.A. is a consultant for drug development at Proctor & Gamble. E.C. has nothing to disclose. D.D. has nothing to disclose. E.D.-K. has nothing to declare. H.F.E.-M. has nothing to disclose. W.F. has nothing to disclose. O.E.J. has nothing to disclose. R.S.L. is a consultant for Glaxo Smith Kline, Ferring, Quat. Rx, Organon, Serono, and Solvay. R.J.N. has nothing to disclose. A.E.T. is an employee of Novartis. S.F.W. has nothing to disclose.

Formerly the Androgen Excess Society.